Rilpivirine - NDSRI's
References
FAQ's
References
- Guillemont, Jerome Emile Georges; Palandjian, Patrice; De Jonge, Marc Rene; Koymans, Lucien Maria Henricus; Vinkers, Hendrik Maarten; Daeyaert, Frederik Frans Desire; Heeres, Jan; Van Aken, Koen Jeanne Alfons; Lewi, Paulus Joannes; Janssen, Paul Adriaan Jan, HIV inhibiting pyrimidines derivatives, Janssen Pharmaceutica N.V., Belgium, EP1419152B1, July 27, 2011
- Masthanamma, S. K.; Gottumukkala, Alekhya, Development and validation of UV spectrophotometric methods for estimation of rilpivirine in bulk and pharmaceutical formulation, International Journal of Pharmaceutical Sciences and Research, Volume: 5, Issue: 2, Pages: 483-489 2014
Frequently Asked Questions
Are there specific Rilpivirine impurities that can interact with other medications or substances?
Rilpivirine impurities may have the potential to interact with other medications or substances.
What measures are taken during the manufacturing process to minimize the formation of Rilpivirine impurities?
Stringent manufacturing processes and quality control measures, like careful selection of starting materials, optimized reaction conditions, and purification techniques, help minimize the formation of impurities during the manufacturing of Rilpivirine.
Can the presence of Rilpivirine impurities lead to variations in its pharmacological effects or patient response?
Rilpivirine impurities can cause variations in its pharmacological effects or patient response.
What are the temperature conditions required to store Rilpivirine impurities?
Rilpivirine impurities should be stored at a controlled room temperature between 2-8°C or as indicated on the Certificate of Analysis (CoA).
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.